Search - tctmd.com

Displaying 1 - 9 of 9

Sort: Relevancy | Date

News Conference News TCT 2020

Encouraging Results Seen for TAVR in Failed Surgical or TAVR Valves

Todd Neale

October 17, 2020

News Conference News TCT 2019

Long-term PARTNER 2A Results Put Spotlight on Paravalvular Leak in TAVR

Todd Neale

September 29, 2019

News Daily News TCT 2018

High Mortality but Durable Results With Valve-in-Valve TAVR

Michael O'Riordan

September 23, 2018

Presentation TCT 2018

TCT-73: Treatment of Severe TRIcuspid Regurgitation in Patients with Advanced Heart Failure with CAval Vein Implantation of the Edwards Sapien XT VALve (TRICAVAL): a controlled prospective randomized trial

Presenter: Rebecca T. Hahn, Jose Luis Navia, Maurizio Taramasso, Henryk Dreger

September 21, 2018

News Conference News TCT 2017

A-fib Signals Worse Prognosis After Aortic Valve Replacement in Intermediate-Risk Patients

Todd Neale

November 08, 2017

News Conference News TCT 2017

One in Six Patients With LBBB Post-TAVR Develop Atrioventricular Block

Michael O'Riordan

October 31, 2017

News Conference News TCT 2017

Intermediate-Risk TAVR Substantially More Cost-effective Than Surgery

Yael L. Maxwell

October 31, 2017

‘Promising’ SENTINEL Cerebral Protection in TAVR Collects Debris but Misses Primary Endpoint

News Conference News TCT 2016

Sentinel Cerebral Protection Device in TAVR ‘Promising’ but Trial Misses Primary Endpoint

Shelley Wood

November 01, 2016

News Industry News TCT 2016

Patients With Sever Aortic Stenosis And Intermediate Surgical Risk Show Similar Late Quality of Life Outcomes Following Either Transcatheter or Surgical Aortic Valve Replacement

November 01, 2016

Advertisement

Encouraging Results Seen for TAVR in Failed Surgical or TAVR Valves

Long-term PARTNER 2A Results Put Spotlight on Paravalvular Leak in TAVR

High Mortality but Durable Results With Valve-in-Valve TAVR

TCT-73: Treatment of Severe TRIcuspid Regurgitation in Patients with Advanced Heart Failure with CAval Vein Implantation of the Edwards Sapien XT VALve (TRICAVAL): a controlled prospective randomized trial

A-fib Signals Worse Prognosis After Aortic Valve Replacement in Intermediate-Risk Patients

One in Six Patients With LBBB Post-TAVR Develop Atrioventricular Block

Intermediate-Risk TAVR Substantially More Cost-effective Than Surgery

Sentinel Cerebral Protection Device in TAVR ‘Promising’ but Trial Misses Primary Endpoint

Patients With Sever Aortic Stenosis And Intermediate Surgical Risk Show Similar Late Quality of Life Outcomes Following Either Transcatheter or Surgical Aortic Valve Replacement

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content